Overview A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma Status: Unknown status Trial end date: 2017-04-01 Target enrollment: Participant gender: Summary This is a phase 2 study to evaluate the efficacy of single-agent icotinib in patients with advanced nasopharyngeal carcinoma. Phase: Phase 2 Details Lead Sponsor: Betta Pharmaceuticals Co., Ltd.Betta Pharmaceuticals Co.,Ltd.